Limited use of ESAs

Limited use of ESAs

Limited use of ESAs
CMS has proposed limited coverage of ESAs for anemia in cancers where the presence of erythropoietin receptor on either

Read the full 270 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE